secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K
Filed at:   2026-08-21T21:12:40+00:00
Accession:  0001213900-26-092680
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apimeds acquires Apitox rights from FreeT: Korean clinic market, 25% US royalty
-------------------------------------------------------------------------------

- On Aug 19, 2026, Apimeds entered an Assignment Agreement with FreeT Inc. (successor to CNP Roen/Inscobee).
- Assigned rights include 100% of Apitox Korean medicine-clinic market rights and 25% royalty on US Apitox economic proceeds.
- Also granted 25% revenue participation on net proceeds from overseas rights deals plus quarterly clinical and commercialization updates.
- Company assumes no pre-effective-date liabilities; rights exclude global rights not held by FreeT and underlying Apitox IP.
- FreeT will support continued development and expansion and pursue future grants of non-US Apitox territories to Apimeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026092680/0001213900-26-092680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026092680/ea0303076-8k_apimeds.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-092680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer